EE424 Societal Costs of Spinal Muscular Atrophy Type 1 for Patients Treated with Onasemnogene Abeparvovec or Nusinersen in the United Kingdom
Abstract
Authors
J Kleintjens A Patel M van Keep K Srivastava P McHale S Affinito M Bischof